Down 9% in 2020, Is Biogen Now a Buy?
Biogen (NASDAQ: BIIB) had a wild 2020. In November, reviewers from the Food and Drug Administration (FDA) seemed to endorse the company's potential Alzheimer's drug aducanumab, sending the shares up 44%. A few days later, an advisory panel overwhelmingly said there was not strong evidence that the drug was effective, sending shares back down.
An official decision will come by March. While investors wait, a lot is happening at the $36 billion biotech company.
Image source: Getty Images
Source Fool.com
